Author’s response to reviews

Title: Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease

Authors:

Ken Aizawa (aizawa.ken85@chugai-pharm.co.jp)
Ryohei Kawasaki (kawasaki.ryohei20@chugai-pharm.co.jp)
Yoshihito Tashiro (tashiro.yoshihito71@chugai-pharm.co.jp)
Yasushi Shimonaka (yancha1206@ab.cyberhome.ne.jp)
Michinori Hirata (hiratamcn@chugai-pharm.co.jp)

Version: 2 Date: 04 Jan 2018

Author’s response to reviews:

January 5, 2018

Dr. Hayley Henderson,

Editor-in-Chief, BMC Nephrology

Dear Dr. Henderson,

Please find attached a manuscript entitled “Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease” by Ken Aizawa et al.

This manuscript is a final version revised in accordance with editor’s comments; the figure titles were amended and the additional statement was added in the ‘Funding’ declaration. We hope that these modifications meet your satisfaction.

Thank you for your kind consideration of our manuscript for publication in BMC Nephrology.

Sincerely yours,

Ken Aizawa, Ph.D.,
Product Research Department, Medical Affairs Division, Chugai Pharmaceutical Co., Ltd.
200 Kajiwara, Kamakura 247-8530, Japan.
Phone: +81-467-45-6901, Fax: +81-467-45-7643
E-mail: aizawa.ken85@chugai-pharm.co.jp